The patent is entitled, Method for activating natural killer cells by tumor cell preparation in vitro and has a current expiration date of July 2027.
CNDO-109 activates the immune system’s NK cells to seek and destroy cancer cells.
The biologic,CNDO-109, demonstrated activity in multiple myeloma, breast cancer, prostate cancer and ovarian cancer in preclinical studies.
The company plans to begin a Phase 1/2 dose escalation trial in AML patients in the second half of 2012.